| Registered office: |
Hofackerstrasse 8, P.O. Box 932, 4132 Muttenz/Switzerland | |
| Phone: Fax: |
+41 61 279 90 00 +41 61 279 90 09 |
|
| http://www.wild-pharma.com E-Mail: info@wild-pharma.com |
||
| Production site: | Hofackerstrasse 8 CH-4132 Muttenz/Switzerland |
|
| Foundation: | 1932 | |
| Organization: | Family joint stock, company with a paid capital of CHF 1'000'000.- | |
| Management: | Dr. iur. Armin Stieger, president of the board |
|
| Dr. chem. Rolf Wild, vice-president of the board |
||
| Sven Wild, delegate of the board and CEO |
||
| Werner Schmid, member of the board | ||
| Rozalia Wild, member of the board | ||
| Pietro Petriella, export director | ||
| Roger Aebi, export manager | ||
| Tri-Dien Luu, technical director, member of the management |
||
| Dr. Andreas Hasler, MSc-ETH, KMU-HSG, marketing & sales director, member of the management |
||
| Stefan Karth, production manager | ||
| Activities: | Research, development, manufacture, distribution of pharmaceutical and cosmetic products. Products for dental and oral hygiene | |
| Representative Office Middle East: |
ACTCO, Larnaca, Cyprus |
|
| Production under licence: |
Egypt, France, Greece, India, Morocco, Portugal, Spain, Thailand |
|
| Member of: | ASSGP | Association Suisse des Fabricants de Spécialités Grand Public |
| AESGP | The European Self-Medication Industry | |
| ASCID | Association Suisse de l'Industrie et du Commerce Dentaire |
|
| SGCI | Swiss Society of Chemical Industries | |
| SZH | Swiss Office for the Development of Trade | |
| Standards of reference | Good practice in the manufacture of drugs and cosmetics according to the Swiss regulations in force and in accordance with the requirements for good manufacturing practices and quality control as recommended by the World Health Organization. | |
| History Dr. Wild & Co. AG was founded in 1932 by Dr Samuel Wild and Werner Wild as an independent and self-supporting company, which it still is. At the time, it was a great challenge to take up the development, manufacture and quality control of medicines. Until the end of the second World War, the main market was Switzerland. In the 1940ies a whole range of dental care products was developed and manufactured thanks to a close and fruitful collaboration with dental universities and physicians. During this pioneering work, Dr Wild succeeded in adding therapeutically active ingredients to toothpastes, mouthwashes, gingival pastes and gels. The first products to appear on the market were the EMOFORM Recently Dr Wilds dental research department succeeded in stabilising the efficacious and clinically well-documented stannous-II-fluoride for treating sensitive toothnecks, irritated gums and as prophylaxis of enamel and dentine caries. Consequently EMOFLUOR The EMOFLUOR The tea tree leaves have been used for their antimicrobial properties for several thousand years by the Bundjabung aborigines of Australia. Dr Wild's Dental Research Department has developped TEBODONT Dr Wilds dental research department will continue to develop innovative products, that meet the requirements of dental and oral care. |